Bayer Aktiengesellschaft (ETR:BAYN)
38.05
+1.60 (4.39%)
Apr 30, 2026, 5:39 PM CET
Bayer Aktiengesellschaft Revenue
In the year 2025, Bayer Aktiengesellschaft had annual revenue of 45.58B EUR, down -2.21%. Bayer Aktiengesellschaft had revenue of 11.44B in the quarter ending December 31, 2025, a decrease of -2.48%.
Revenue
45.58B
Revenue Growth
-2.21%
P/S Ratio
0.82
Revenue / Employee
522.17K
Employees
87,280
Market Cap
37.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.58B | -1.03B | -2.21% |
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | 43.55B | 6.80B | 18.52% |
| Dec 31, 2018 | 36.74B | 1.73B | 4.93% |
| Dec 31, 2017 | 35.02B | 72.00M | 0.21% |
| Dec 31, 2016 | 34.94B | -11.14B | -24.18% |
| Dec 31, 2015 | 46.09B | 4.75B | 11.48% |
| Dec 31, 2014 | 41.34B | 1.18B | 2.94% |
| Dec 31, 2013 | 40.16B | 416.00M | 1.05% |
| Dec 31, 2012 | 39.74B | 3.21B | 8.80% |
| Dec 31, 2011 | 36.53B | 1.44B | 4.10% |
| Dec 31, 2010 | 35.09B | 3.92B | 12.58% |
| Dec 31, 2009 | 31.17B | -1.75B | -5.32% |
| Dec 31, 2008 | 32.92B | 533.00M | 1.65% |
| Dec 31, 2007 | 32.39B | 32.19B | 16,422.96% |
| Dec 31, 2006 | 196.00M | -24.51B | -99.21% |
| Dec 31, 2005 | 24.70B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.30B |
| Fresenius SE & Co. KGaA | 22.87B |
| Merck KGaA | 21.10B |
| Fresenius Medical Care AG | 19.63B |
| Sartorius Aktiengesellschaft | 3.55B |
| Drägerwerk AG & Co. KGaA | 3.51B |
| Fielmann Group AG | 2.44B |
| Carl Zeiss Meditec AG | 2.20B |
Bayer Aktiengesellschaft News
- 2 days ago - House strips MAHA-hated pesticide provisions from farm bill - CNBC
- 3 days ago - Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian - Business Wire
- 3 days ago - New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing - Business Wire
- 4 days ago - Trump draws criticism from MAHA base over weed killer glyphosate - CNBC
- 4 days ago - Bayer Faces Critical Supreme Court Debate Over Roundup Lawsuits - GuruFocus
- 4 days ago - Bayer Faces Supreme Court Challenges Over Roundup Lawsuits (BAYRY) - GuruFocus
- 4 days ago - Bayer Stock Plunges As Supreme Court Wrestles With Roundup Cancer Suits - Benzinga
- 4 days ago - Bayer shares slide after U.S. Supreme Court split over Bayer's fight against Roundup lawsuits - Reuters